+1 (888) 794-0077
« Return

Providing Support for Drug Discovery and Non-GLP Bioanalysis

Speed is essential for your in vitro and in vivo screening during drug discovery. Whether you are developing a small or large molecule drug, working with the right bioanalytical team is essential to your success. Look for a partner that provides comprehensive services that include method development, method qualification and sample collection protocol design. Your partner should deliver the right structure, procedures, and data quality that is needed for a successful drug candidate.

Experience a bioanalytical team that offers one of the most extensive technology platforms for small and large molecule bioanalysis. It is comprised of industry-leading instrumentation to support regional and global studies with rapid, precise and reproducible results. Using an existing library of validated methods and state-of-the-art instrumentation, our experienced discovery bioanalytical team has successfully expedited numerous projects to completion.

The bioanalytical team at WuXi AppTec offers optimized project workflows and robust state-of-the-art technology platforms that can rapidly develop and validate methods to support your drug discovery efforts for small and large molecule development. This includes biomarkers, immunogenicity and pharmacokinetic (PK) studies. Learn more about our non-GLP bioanalytical services by watching the video below.

Follow WuXi AppTec Laboratory Testing Division on LinkedIn for industry insights and program support.

Established in December 2000, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec’s open-access platform is enabling more than 4,000 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that “every drug can be made and every disease can be treated”.

Related Articles

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Bioanalytical Strategies for Evaluating Immunogenicity in Next-Generation AAV Therapies

Next-generation AAV (adeno-associated virus) therapies have recently emerged as a significant area of therapeutic innovation to address complex or inherited diseases. They offer a potential pathway to treat conditions once deemed untreatable through methods like replacement, inactivation, or introduction of new materials. Viral vectors are essential for delivering these advanced therapies, as they efficiently transport therapeutic material into target cells. Once inside the cell, the vector incorporates into the host’s natural machinery, enabling protein expression and facilitating treatment outcomes.

Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage

Advancing Oligonucleotide Drug Development with Ligand Binding Assays in the Preclinical Stage

The development of oligonucleotide drugs has seen remarkable progress, driven by innovations in chemical modifications and delivery systems. These advancements have significantly enhanced drug stability, extended half-life, and improved targeting capabilities, increasing therapeutic efficacy and reducing dosage frequency. However, these benefits come with unique challenges in preclinical bioanalysis, particularly in pharmacokinetics (PK), drug metabolism, and tissue distribution studies.